Organogenesis Holdings Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Organogenesis Holdings şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

0.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	0.2%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Organogenesis: Lurking Disruption With Recovery To Follow

Oct 15

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Sep 09

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ORGO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ORGO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Organogenesis Holdings Piyasaya Karşı Temettü Getirisi

ORGO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ORGO)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (ORGO) (3 yıla kadar)	0%

Önemli Temettü: ORGO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ORGO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ORGO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ORGO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Organogenesis Holdings Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Consensus estimates of losses per share improve by 64%

Price target increased by 7.4% to US$4.70

Organogenesis Holdings Inc. announced that it expects to receive $130 million in funding from Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P

New minor risk - Share price stability

Organogenesis Holdings Inc. announced that it expects to receive $130 million in funding from Avista Healthcare Partners

Organogenesis Holdings Inc. Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Organogenesis Holdings Inc. to Report Q3, 2024 Results on Nov 12, 2024

Organogenesis: Lurking Disruption With Recovery To Follow

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Consensus EPS estimates fall by 492%

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.04 profit in 2Q 2023)

Organogenesis Holdings Inc. Shares Renu Program Update

Investor sentiment deteriorates as stock falls 18%

Organogenesis Holdings Inc. to Report Q2, 2024 Results on Aug 08, 2024

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Price target decreased by 11% to US$4.17

Consensus EPS estimates fall by 267%

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Investor sentiment improves as stock rises 25%

Consensus EPS estimates upgraded to US$0.01 loss

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

First quarter 2024 earnings released: US$0.016 loss per share (vs US$0.023 loss in 1Q 2023)

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Investor sentiment deteriorates as stock falls 20%

Organogenesis Holdings Inc. to Report Q1, 2024 Results on May 09, 2024

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Chief Operating Officer exercised options to buy US$432k worth of stock.

Consensus EPS estimates fall from profit to US$0.013 loss

New minor risk - Earnings quality

Full year 2023 earnings: EPS and revenues miss analyst expectations

Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024

Investor sentiment improves as stock rises 20%

Organogenesis Holdings Inc. to Report Q4, 2023 Results on Feb 29, 2024

Insider recently sold US$77k worth of stock

Investor sentiment improves as stock rises 17%

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Investor sentiment improves as stock rises 22%

Consensus forecasts updated

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 15%

High number of new directors

Organogenesis Holdings Inc. to Report Q3, 2023 Results on Nov 09, 2023

Organogenesis Holdings Inc. Withdraws Earnings Guidance for the the 2023

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 16%

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Investor sentiment deteriorates as stock falls 15%

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Investor sentiment improves as stock rises 23%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improves as stock rises 16%

Insider recently sold US$104k worth of stock

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorates as stock falls 17%

Organogenesis Holdings Inc. to Report Q4, 2022 Results on Mar 01, 2023

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.098 in 3Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Organogenesis Holdings Inc. to Report Q3, 2022 Results on Nov 09, 2022

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Investor sentiment deteriorated over the past week

Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Second quarter 2022 earnings: EPS misses analyst expectations